原肌球蛋白受体激酶(TRK)抑制剂的研究进展
文献类型：期刊论文
| 作者 | 杨竣喆1,2; 许子超2; 李淳朴2; 程远征1; 柳红1,2
|
| 刊名 | 有机化学
 |
| 出版日期 | 2022-07 |
| 卷号 | 42期号:7页码:2055-2069 |
| 关键词 | tropomyosin receptor kinase anticancer inhibitor |
| ISSN号 | 0253-2786 |
| DOI | 10.6023/cjoc202112020 |
| 其他题名 | Research Progress of Tropomyosin Receptor Kinase (TRK) Inhibitors |
| 文献子类 | Review |
| 英文摘要 | Tropomyosin receptor kinase (TRK) is a tyrosine kinase family activated by nerve growth factor, including TRKA, TRKB and TRKC, which are encoded by NTRK1 (neurorosine receptor tyrosine kinase 1), NTRK2 and NTRK3 genes, respectively. After phosphorylation, TRK kinase can activate downstream signaling molecules, and then regulate cell proliferation, differentiation, metabolism and apoptosis. The NTRK gene can fuse with other genes, resulting in high kinase expression or continuous increase of kinase activity, leading to cancer. The main strategy for targeting NTRK fusion genes is to develop small molecule inhibitors of TRK that act on the intracellular kinase region. In recent years, the development of TRK small molecule inhibitors has also attracted the attention of researchers. The structure, physiological function, TRK inhibitors and therapeutic strategies to overcome drug resistance of TRK kinase are reviewed. |
| WOS关键词 | ANALOG SECRETORY CARCINOMA ; SMALL-MOLECULE INHIBITOR ; PAN-TRK ; ACQUIRED-RESISTANCE ; NEUROTROPHIC FACTOR ; TYROSINE KINASES ; BROAD-SPECTRUM ; GROWTH-FACTOR ; POTENT ; IDENTIFICATION |
| WOS研究方向 | Chemistry |
| 语种 | 中文 |
| WOS记录号 | WOS:000853272500011 |
| 出版者 | SCIENCE PRESS |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/309331]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | 程远征; 柳红 |
| 作者单位 | 1.Weifang Med Coll, Sch Pharm, Weifang 261053, Shangdong, Peoples R China; 2.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China |
| 推荐引用方式 GB/T 7714 | 杨竣喆,许子超,李淳朴,等. 原肌球蛋白受体激酶(TRK)抑制剂的研究进展[J]. 有机化学,2022,42(7):2055-2069. |
| APA | 杨竣喆,许子超,李淳朴,程远征,&柳红.(2022).原肌球蛋白受体激酶(TRK)抑制剂的研究进展.有机化学,42(7),2055-2069. |
| MLA | 杨竣喆,et al."原肌球蛋白受体激酶(TRK)抑制剂的研究进展".有机化学 42.7(2022):2055-2069. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。